In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guest Donald Thomas, M.D., a rheumatologist and lupus researcher. They discuss how Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, is enhancing the care and quality of life for patients affected by systemic lupus erythematosus (SLE).
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guests Bernard Rubin, D.O., MPH, chief medical officer of Progentec Diagnostics, and Melissa Munroe, M.D., Ph.D., chief scientific officer and principal investigator of Progentec Diagnostics. They discuss Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, for patients affected by systemic lupus erythematosus (SLE).
As a successful outcome of the collaboration announced in 2023, Progentec’s proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available through Mayo Clinic Laboratories.
Mayo Clinic Laboratories, a leading global reference laboratory, and Progentec Diagnostics, a digital health and biomarker technology-based company focused on autoimmune conditions, today announced a strategic collaboration to bring Progentec’s suite of proprietary biomarker blood tests for the proactive management of autoimmune diseases to market. The collaboration aims to increase accessibility for providers and patients across the U.S. and select global markets.